ES2183184T3 - Derivados seleccionados del compuesto k-252a. - Google Patents

Derivados seleccionados del compuesto k-252a.

Info

Publication number
ES2183184T3
ES2183184T3 ES97927906T ES97927906T ES2183184T3 ES 2183184 T3 ES2183184 T3 ES 2183184T3 ES 97927906 T ES97927906 T ES 97927906T ES 97927906 T ES97927906 T ES 97927906T ES 2183184 T3 ES2183184 T3 ES 2183184T3
Authority
ES
Spain
Prior art keywords
compound
selected derivatives
derivatives
survival
enhancing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97927906T
Other languages
English (en)
Inventor
Robert L Hudkins
John P Mallamo
Masami Hamano
Reiko Tanaka
Chikara Murakata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Cephalon LLC
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd, Cephalon LLC filed Critical Kyowa Hakko Kogyo Co Ltd
Application granted granted Critical
Publication of ES2183184T3 publication Critical patent/ES2183184T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA PRESENTE INVENCION DESCRIBE DERIVADOS DE INDOLOCARBAZOL SELECCIONADOS QUE SE REPRESENTAN POR LA FORMULA (I). DICHOS COMPUESTOS SON UTILES PARA MEJORAR LA FUNCION Y/O SUPERVIVENCIA DE UNA CELULA SENSIBLE AL FACTOR TROFICO. DICHOS COMPUESTOS INHIBEN LA PRODUCCION DE INTERLEUQUINA 2 Y TIENEN ACTIVIDAD INMUNOSUPRESORA.
ES97927906T 1996-06-03 1997-06-02 Derivados seleccionados del compuesto k-252a. Expired - Lifetime ES2183184T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65736696A 1996-06-03 1996-06-03

Publications (1)

Publication Number Publication Date
ES2183184T3 true ES2183184T3 (es) 2003-03-16

Family

ID=24636859

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97927906T Expired - Lifetime ES2183184T3 (es) 1996-06-03 1997-06-02 Derivados seleccionados del compuesto k-252a.

Country Status (17)

Country Link
US (1) US6306849B1 (es)
EP (1) EP0918777B1 (es)
JP (1) JP2000511902A (es)
CN (1) CN1198827C (es)
AT (1) ATE222912T1 (es)
AU (1) AU716656B2 (es)
BR (1) BR9711093A (es)
CA (1) CA2256633C (es)
DE (1) DE69715010T2 (es)
DK (1) DK0918777T3 (es)
ES (1) ES2183184T3 (es)
NO (1) NO312464B1 (es)
NZ (2) NZ333018A (es)
PT (1) PT918777E (es)
RU (1) RU2205184C2 (es)
UA (1) UA67725C2 (es)
WO (1) WO1997046565A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
EP1126855B1 (en) * 1998-09-25 2007-05-09 Cephalon, Inc. Use of fused pyrrolocarbazoles for preventing/treating damage to sensory hair cells and cochlear neurons
US7129250B2 (en) 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
AU2003259846A1 (en) * 2002-08-16 2004-03-03 The General Hospital Corporation Non-invasive functional imaging of peripheral nervous system activation in humans and animals
CA2500901A1 (en) * 2002-10-04 2004-04-22 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
WO2005000194A2 (en) * 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
ZA200502612B (en) 2002-10-08 2007-07-25 Rinat Neuroscience Corp Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
DK2270048T3 (en) 2002-12-24 2016-01-18 Rinat Neuroscience Corp Anti-NGF antibodies and methods for their use
BRPI0407375A (pt) * 2003-02-19 2006-02-07 Rinat Neuroscience Corp Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
EP3372614B1 (en) 2004-04-07 2022-06-08 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
NZ593438A (en) * 2008-12-22 2012-12-21 Creabilis S A Synthesis of polymer conjugates of indolocarbazole compounds

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554402A (en) 1983-12-23 1985-11-19 Aluminum Company Of America Vibration damper for overhead conductor
JPS62120388A (ja) 1985-11-19 1987-06-01 Meiji Seika Kaisha Ltd Ｓｆ−２３７０物質ハロゲン化誘導体とその製造法
JPS62155284A (ja) 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPS62155285A (ja) 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPS62220196A (ja) 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd 新規物質ｕｃｎ―０１
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
JPH0826036B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
JPH0826037B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
US4735939A (en) 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
US4923986A (en) 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
EP0383919A4 (en) 1988-02-04 1992-08-05 Kyowa Hakko Kogyo Co., Ltd. Staurosporin derivatives
DE3835842A1 (de) * 1988-10-21 1990-04-26 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE3924538A1 (de) 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
AU7035991A (en) 1989-12-14 1991-07-18 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951 atcc 53856
US5168103A (en) * 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
JPH0586068A (ja) 1991-03-04 1993-04-06 Rikagaku Kenkyusho 新規抗生物質ｒｋ−１４０９、その製造法並びに抗腫瘍剤及び抗炎症剤
JPH07505124A (ja) 1991-11-08 1995-06-08 ザ ユニバーシティ オブ サザン カリフォルニア ニューロトロフィン活性増強のためのｋ−２５２化合物を含む組成物
JP2593021B2 (ja) 1991-12-13 1997-03-19 伊藤ハム株式会社 ウシ胚の性の識別方法
US6271242B1 (en) 1992-02-10 2001-08-07 Bristol-Myers Squibb Co. Method for treating cancer using a tyrosine protein kinase inhibitor
JPH05247055A (ja) 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
JPH0673063A (ja) 1992-06-22 1994-03-15 Kyowa Hakko Kogyo Co Ltd Ｕｃｎ−０１誘導体
US5344926A (en) 1992-06-22 1994-09-06 Kyowa Hakko Kogyo Co., Ltd. Process for producing staurosporine derivatives
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
CA2123895A1 (en) 1992-09-21 1994-03-31 Tatsuya Tamaoki A therapeutic agent for thrombocytopenia
AU679752B2 (en) 1993-05-28 1997-07-10 Cephalon, Inc. Use of indolocarbazole derivatives to treat a pathological condition of the prostate
AU7000094A (en) 1993-06-17 1995-01-17 Ciba-Geigy Ag Indolocarbazole compound useful as proteinkinase c inhibitor
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders

Also Published As

Publication number Publication date
HK1018703A1 (en) 1999-12-30
NO985622L (no) 1999-02-02
JP2000511902A (ja) 2000-09-12
WO1997046565A1 (en) 1997-12-11
CN1226893A (zh) 1999-08-25
NZ504097A (en) 2005-06-24
ATE222912T1 (de) 2002-09-15
PT918777E (pt) 2003-01-31
CN1198827C (zh) 2005-04-27
AU3225397A (en) 1998-01-05
AU716656B2 (en) 2000-03-02
RU2205184C2 (ru) 2003-05-27
NO985622D0 (no) 1998-12-02
DE69715010D1 (de) 2002-10-02
CA2256633A1 (en) 1997-12-11
US6306849B1 (en) 2001-10-23
DE69715010T2 (de) 2003-04-03
UA67725C2 (en) 2004-07-15
BR9711093A (pt) 1999-08-17
NZ333018A (en) 2000-05-26
EP0918777A1 (en) 1999-06-02
EP0918777B1 (en) 2002-08-28
CA2256633C (en) 2009-04-07
DK0918777T3 (da) 2002-12-30
NO312464B1 (no) 2002-05-13

Similar Documents

Publication Publication Date Title
ES2183184T3 (es) Derivados seleccionados del compuesto k-252a.
AU1676200A (en) Polyhydroxylated heterocyclic derivatives as anti-coagulants
MY126559A (en) Fungicidal 2-methoxybenzophenones
MY137566A (en) Indolylmaleimide derivatives
EP0630898A4 (en) MEDICINE FOR THROMBOZYTOPENIA.
SE8204817D0 (sv) Tetrazine derivatives
ATE289810T1 (de) Ecteinascidinderivate
DE3671894D1 (de) Penemverbindungen, ihre herstellung und verwendung.
ATE165357T1 (de) Neue verwendung bis-heterocyclische verbindungen und dessen zusammensetzungen
AU5377190A (en) Improvements in or relating to organic compounds
DE69727305D1 (de) Verwendung neurogen-entzuendungshemmender verbindungen und zusammensetzungen
WO2001023392A8 (en) Tetracyclic benzimidazole derivatives and combinatorial libraries thereof
MY109069A (en) Fungicidal derivatives of 2-alkoxy-2-imidazolin-5-ones
SE9604582D0 (sv) Novel compounds
DE69910568D1 (de) Furopyridinderivate und ihre therapeutische verwendung
DE69812177T2 (de) 3'-epi k-252a derivate
AU4733185A (en) Proline derivatives
DE69703115D1 (de) Zwischenprodukte um 2-imidazolin-5onederivate herzustellen.
DE69706950D1 (de) Furoindolizine
TR200002749T2 (tr) Antibiyotikler olarak siklik aminoguanidin substitüentlerine sahip sefalosporinler.
CA2187849A1 (en) Uck14 compounds
IL86665A0 (en) Mitomycin analogs
GB9911556D0 (en) Immunosuppressant tricyclic compounds
CA2201219A1 (en) Process for the preparation of substituted pyrimidines